KALY Conducts Cannabis Extraction Lab Site Survey For NOUV 100 Acer Hemp Farm
May 07 2019 - 9:42AM
InvestorsHub NewsWire
KALY Conducts Cannabis Extraction
Lab Site Survey For NOUV 100 Acer Hemp Farm
Dallas, TX -- May 7, 2019 --
InvestorsHub NewsWire -- Kali-Extracts, Inc. (Kali, Inc.
dba/Kali-Extracts, Inc.) (USOTC:
KALY) (“KALY”) today announced CEO Frederick Ferri is leading a
site survey today of the cannabis extraction lab KALY is building in partnership with Nouveau
(USOTC:
NOUV) (“NOUV”) to facilitate extraction in conjunction with
NOUV’s previously announced 100 acer hemp farm. NOUV
currently operates a 25-greenhouse growing operation and in
partnership with KALY plans to build an additional state-of-the-art
greenhouse for the purpose of developing a proprietary cannabis
cultivar.
Patented Cannabis Extracts
Targeting $170 In Million Pharmaceutical
Treatments
In the
fourth quarter of last year, 2018, KALY acquired NCM Biotech
(NCMB). NCMB is biopharmaceutical company focused on
discovering, developing and commercializing novel therapeutics from
a proprietary cannabinoid product platform in a broad range of
disease areas. In four years of operations, the company has
established a leading position in the development of plant-derived
cannabinoid therapeutics through a proven drug discovery and
patented development process. The resulting intellectual
property portfolio and the established regulatory and manufacturing
expertise have created a significant opportunity. KALY,
through its subsidiary, NCMB has a deep pipeline of additional
cannabinoid product candidates including four distinct
compounds. KALY has completed the first stage of clinical
development and testing for a Chronic Obstructive Pulmonary Disease
(COPD) therapy and is currently conducting phase one development
and trials for compounds targeting Cancer Pain Management, Type 2
Diabetes and Epilepsy.
$170 Million Cannabis Therapeutics Market
Opportunity
- Chronic
Obstructive Pulmonary Disease (COPD) - The market for COPD
treatment is anticipated to reach $14 billion by 2025;
- Type 2
Diabetes - The market for Type 2 Diabetes is expected to be
a $64 billion market by 2026;
- Cancer
Pain Management - The overall pain
management treatment market is anticipated to reach $83 billion by 2024, and
- Epilepsy
- The market for epilepsy
treatment is anticipated to reach $9 billion by 2022.
$1
Million 2019 Revenue Target From Parallel Revenue
Strategy
KALY is
not relying on its biopharmaceutical development strategy alone to
insure the company’s long-term success. With the popularity
of cannabis extracts for infusion into various consumer products,
KALY’s patented extraction process offers arguably the highest
quality extract to the infusion market. Drawing on KALY’s
patented cannabis extraction expertise, Puration’s (USOTC:
PURA) EVERx CBD Sports Water is already the leading CBD infused
beverage for the sports nutrition market. KALY has also
introduced its own CBD confections line, Hemp4mula with CBD infused
gum already on the market and gummies on the way. Hemp4mula
is expected to be available on the Ecommerce site USMJ.com hosted by North American Cannabis
Holdings, Inc. (USOTC:
USMJ) (aka USMJ). KALY has also entered into a
partnership with Nouveau (USOTC:
NOUV), a cannabis cultivation company, with plans to develop a
proprietary cannabis cultivar that can further enhance the quality
of KALY’s extracts. KALY’s consumer revenue strategy offers a
business line that can stand alone, but one that also provides KALY
with the long-term staying power to take the necessary time to
bring its cannabis extract biopharmaceutical products to
market. Currently, KALY management anticipates that its $1
million 2019 revenue goal for its parallel consumer market strategy
is well within reach.
To learn more about the company
visit https://www.kali-extracts.com/
This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended (the "Exchange Act"),
and as such, may involve risks and uncertainties. These forward
looking statements relate to, amongst other things, current
expectation of the business environment in which the company
operates, potential future performance, projections of future
performance and the perceived opportunities in the market. The
company's actual performance, results and achievements may differ
materially from the expressed or implied in such forward-looking
statements as a result of a wide range of
factors.
CONTACT:
Frederick Ferri
ir@kali-extracts.com
(214) 210-0459
Nouveau Life Pharmaceuti... (PK) (USOTC:NOUV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nouveau Life Pharmaceuti... (PK) (USOTC:NOUV)
Historical Stock Chart
From Sep 2023 to Sep 2024